You may experience a brief disruption in service on Sunday, February 23, between the hours of 3 a.m. and 10 a.m. (CT) due to scheduled website maintenance.
Our password reset feature is not functioning properly and we apologize for the inconvenience. We are working to resolve this issue as quickly as possible. Contact [email protected] for assistance.
Menu
News February 20, 2013

FDA Drug Safety Communication: Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy

Safety Announcement

[2-20-2013] The U.S. Food and Drug Administration (FDA) is updating the public about new actions being taken to address a known safety concern with codeine use in certain children after tonsillectomy and/or adenoidectomy (surgery to remove the tonsils and/or adenoids). Deaths have occurred post-operatively in children with obstructive sleep apnea who received codeine for pain relief following a tonsillectomy and/or adenoidectomy. Codeine is converted to morphine by the liver. These children had evidence of being ultra-rapid metabolizers of codeine, which is an inherited (genetic) ability that causes the liver to convert codeine into life-threatening or fatal amounts of morphine in the body. Read the full announcement.